Methodichlorophen as anti-tumor drug.
Methodichlorophen was given to 26 patients with terminal malignant disease. Eight patients received adequate doses, and five of them showed objective evidence of tumour regression while three failed to respond. Those who responded included four out of five patients with lung cancer (three with squamous-cell carcinoma and one with oat-cell carcinoma) and a patient with hypernephroma. Two patients with testicular teratomas and one with acute myeloid leukemia failed to respond. The drug may be given safely by mouth to outpatients if certain precautions are taken.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents; D001855:Bone Marrow Diseases / Q000139:chemically induced; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002722:Chlorobenzenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004890:Erythema / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011739:Pyrimethamine / Q000031:analogs & derivatives; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D002722:Chlorobenzenes; D011743:Pyrimidines; C006308:metoprine; D002955:Leucovorin; D011739:Pyrimethamine